ctDNA Analysis Enhances MRI-Based (RECIST) Assessment of Response in Clinical Trial of Second-Line Advanced HCC
Time: 12:30 pm
day: Conference Day 1
Details:
- ctDNA highlights molecular responses to resolve lack of clarity from MRI images alone
- Combining ctDNA with MRI allows for broader, and earlier, detection of response in second-line advanced HCC to enhance clinical trial readout
- ctDNA-guided monitoring supports ongoing personalized treatment to improve optimize patient outcomes by elucidating potential basis for immune escape and offering design guidance for updated therapeutics
Personalized Cancer Vaccines
